Skip to main content

Phoebe Starr

Authored Items
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Web Exclusives in Lung Cancer, ASCO Highlights
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
Web Exclusives in Prostate Cancer, ASCO Highlights
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives in ESMO Highlights
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Web Exclusives in AACR Highlights
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
Web Exclusives in ESMO Highlights
Ceritinib Effective in Treating Brain Metastases in NSCLC
Phoebe Starr
Web Exclusives in ESMO Highlights
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
Phoebe Starr
Web Exclusives in ESMO Highlights, PARP Inhibitors
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
Web Exclusives in Lung Cancer
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives in Breast Cancer, ESMO Highlights, CDK4/6 Inhibitors
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
Web Exclusives in ASCO Highlights
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 in ASH Highlights, Venetoclax
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 in ASH Highlights, Venetoclax
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 in ASH Highlights, Immunotherapy
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 in ASH Highlights, Lymphoma
Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma
Phoebe Starr
Web Exclusives in Immunotherapy, Multiple Myeloma
Brigatinib, Next-Generation ALK Inhibitor, Improves Survival versus Crizotinib in Patients with NSCLC and ALK Mutation
Phoebe Starr
Web Exclusives in Lung Cancer
5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
Web Exclusives in Breast Cancer
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
Web Exclusives
Nivolumab plus Ipilimumab Combo Controls Brain Metastases in Patients with Skin Cancer
Phoebe Starr
Web Exclusives in Immunotherapy
Less Is More: Six Months of Traxtuzumab Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
Web Exclusives in Breast Cancer
Immunotherapy Combinations “Raising the Bar”
Phoebe Starr
Web Exclusives in Immunotherapy
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
Web Exclusives
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
Web Exclusives in Immunotherapy
Obinutuzumab Prolongs Survival in Follicular Lymphoma
Phoebe Starr
Web Exclusives in ASH Highlights
CAR T-Cell Therapy Succeeds in Aggressive Lymphoma
Phoebe Starr
Web Exclusives in ASH Highlights
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
Web Exclusives
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Phoebe Starr
Web Exclusives in Tyrosine Kinase Inhibitor
Last modified: June 18, 2020